Bailard Inc. raised its holdings in Sangamo Therapeutics Inc (NASDAQ:SGMO) by 42.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 250,100 shares of the biopharmaceutical company’s stock after buying an additional 74,500 shares during the quarter. Bailard Inc. owned 0.22% of Sangamo Therapeutics worth $2,263,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Capital Wealth Advisors raised its position in shares of Sangamo Therapeutics by 15.6% during the third quarter. Vanguard Capital Wealth Advisors now owns 28,980 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 3,900 shares during the period. Merriman Wealth Management LLC raised its position in shares of Sangamo Therapeutics by 46.7% during the third quarter. Merriman Wealth Management LLC now owns 22,000 shares of the biopharmaceutical company’s stock worth $199,000 after purchasing an additional 7,000 shares during the period. Macquarie Group Ltd. raised its position in shares of Sangamo Therapeutics by 247.8% during the second quarter. Macquarie Group Ltd. now owns 400,000 shares of the biopharmaceutical company’s stock worth $4,308,000 after purchasing an additional 285,000 shares during the period. International Biotechnology Trust PLC raised its position in shares of Sangamo Therapeutics by 212.5% during the second quarter. International Biotechnology Trust PLC now owns 150,000 shares of the biopharmaceutical company’s stock worth $1,616,000 after purchasing an additional 102,000 shares during the period. Finally, First Manhattan Co. acquired a new position in shares of Sangamo Therapeutics during the second quarter worth approximately $32,000. 69.02% of the stock is currently owned by hedge funds and other institutional investors.
SGMO has been the topic of a number of research reports. ValuEngine raised Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. BidaskClub lowered Sangamo Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, October 3rd. HC Wainwright initiated coverage on Sangamo Therapeutics in a research report on Monday, August 26th. They set a “buy” rating and a $16.00 target price on the stock. Zacks Investment Research raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 17th. Finally, Wedbush set a $11.00 price target on Sangamo Therapeutics and gave the company a “hold” rating in a research report on Monday, July 8th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Hold” and an average target price of $14.00.
NASDAQ SGMO opened at $8.32 on Monday. The firm has a market capitalization of $998.28 million, a P/E ratio of -11.88 and a beta of 2.81. The business has a fifty day simple moving average of $9.74 and a 200 day simple moving average of $10.67. Sangamo Therapeutics Inc has a 12 month low of $6.26 and a 12 month high of $14.58.
Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.09. The business had revenue of $17.55 million during the quarter, compared to analyst estimates of $13.58 million. Sangamo Therapeutics had a negative return on equity of 27.32% and a negative net margin of 136.73%. Sangamo Therapeutics’s quarterly revenue was down 18.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.17) EPS. As a group, research analysts anticipate that Sangamo Therapeutics Inc will post -1.32 EPS for the current fiscal year.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
See Also: P/E Growth (PEG)
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.